Abbott Laboratories

Lobbying client

Abbott Laboratories is a large multinational healthcare company based in Illinois, making products across diagnostics, medical devices, pharmaceuticals and nutrition. In city lobbying records, Abbott filed 4 disclosures in 2023 through Pitta Bishop & Del Giorno LLC concerning a city rule on postnatal health, and records show no City Council members were lobbied on that filing. The company has received $3.84 million in city contracts since 2010, with none currently active as of September 2026.

Council members lobbied
None (lobbied 2 city offices)
Filings (since 2021)
4
Lobbying compensation (since 2021)
$75,000
Industry (per city contracts)
Goods
City contracts
none active as of 2026-09-18 · $3,840,076 awarded since 2010
Paid to date
$1,063,657
Won without a fresh bid
81% of contract value · $3,117,966 · 4 contracts
City payments (FY2010-2023)
$1,311,788 · 79 payments
Under registered contracts
$1,103,604 · 84%
Through purchase orders
$208,180 · 16%
Other disbursements
$4 · 0%
Agencies paying it
4
Based in
Desplaines, IL (out of state)

Represented by lobbyist firms

Holds contracts at

Funded by these agencies

Offices and officials lobbied

from the targets named in their filings

What they lobbied on

subjects from their filings

City contracts

Registered city contracts, largest first by current contract value (not amount spent): running now, then registered to start later, then ended. Totals count every registered contract. Each line shows its Checkbook contract ID. The tag on each row is how it was awarded (“no-bid” = non-competitive).

Payments by fiscal year

Every disbursement Checkbook NYC records to this payee, no dollar floor; payments under registered contracts and through purchase orders both count. Fiscal years FY2010-FY2027.

Which agencies pay it

Largest purposes

Grouped by the purpose text on the payment, largest first, no dollar floor. 31 payments totaling $310,364 carry no purpose text; they are in the totals above but not listed here. Fiscal years FY2010-FY2027.

By expense category

Sources